Oren­cia ap­proved by FDA for new in­di­ca­tion — graft vs host dis­ease; So­sei and Twist an­nounce an­ti­body dis­cov­ery deal

For the first time, doc­tors will have a drug to com­bat acute graft-ver­sus-host dis­ease — a dan­ger­ous side ef­fect of stem cell trans­plants in which donor cells at­tack the re­cip­i­ent — be­fore it oc­curs.

The FDA has ap­proved Bris­tol My­ers Squibb’s Oren­cia to pre­vent aGVHD in com­bi­na­tion with cer­tain im­muno­sup­pres­sants, the com­pa­ny an­nounced on Wednes­day. Adults and kids two years and old­er can take the drug if they’re un­der­go­ing hematopoi­et­ic stem cell trans­plan­ta­tion from an un­re­lat­ed re­cip­i­ent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER